These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 32744980)

  • 1. Epigenetic Evaluation of N-(2-hydroxyphenyl)-2-Propylpentanamide, a Valproic Acid Aryl Derivative with Activity Against HeLa Cells.
    Luna-Palencia GR; Correa-Basurto J; Trujillo-Ferrara J; Meraz-Ríos MA; Vásquez- Moctezuma I
    Curr Mol Pharmacol; 2021 Oct; 14(4):570-578. PubMed ID: 32744980
    [TBL] [Abstract][Full Text] [Related]  

  • 2. N-(2-hydroxyphenyl)-2-propylpentanamide, a valproic acid aryl derivative designed in silico with improved anti-proliferative activity in HeLa, rhabdomyosarcoma and breast cancer cells.
    Prestegui-Martel B; Bermúdez-Lugo JA; Chávez-Blanco A; Dueñas-González A; García-Sánchez JR; Pérez-González OA; Padilla-Martínez II; Fragoso-Vázquez MJ; Mendieta-Wejebe JE; Correa-Basurto AM; Méndez-Luna D; Trujillo-Ferrara J; Correa-Basurto J
    J Enzyme Inhib Med Chem; 2016; 31(sup3):140-149. PubMed ID: 27483122
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Docking Studies of Glutamine Valproic Acid Derivative (S)-5- amino-2-(heptan-4-ylamino)-5-oxopentanoic Acid (Gln-VPA) on HDAC8 with Biological Evaluation in HeLa Cells.
    Martínez-Ramos F; Luna-Palencia GR; Vásquez-Moctezuma I; Méndez-Luna D; Fragoso-Vázquez MJ; Trujillo-Ferrara J; Meraz-Ríos MA; Mendieta-Wejebe JE; Correa-Basurto J
    Anticancer Agents Med Chem; 2016; 16(11):1485-1490. PubMed ID: 26845132
    [TBL] [Abstract][Full Text] [Related]  

  • 4.
    Contis-Montes de Oca A; Rodarte-Valle E; Rosales-Hernández MC; Abarca-Rojano E; Rojas-Hernández S; Fragoso-Vázquez MJ; Mendieta-Wejebe JE; Correa-Basurto AM; Vázquez-Moctezuma I; Correa-Basurto J
    Oncotarget; 2018 Sep; 9(70):33368-33381. PubMed ID: 30279967
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of the anticancer properties of a novel valproic acid prodrug to leading histone deacetylase inhibitors.
    Tarasenko N; Chekroun-Setti H; Nudelman A; Rephaeli A
    J Cell Biochem; 2018 Apr; 119(4):3417-3428. PubMed ID: 29135083
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Differential effects of class I isoform histone deacetylase depletion and enzymatic inhibition by belinostat or valproic acid in HeLa cells.
    Dejligbjerg M; Grauslund M; Litman T; Collins L; Qian X; Jeffers M; Lichenstein H; Jensen PB; Sehested M
    Mol Cancer; 2008 Sep; 7():70. PubMed ID: 18789133
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Teratogenic effects mediated by inhibition of histone deacetylases: evidence from quantitative structure activity relationships of 20 valproic acid derivatives.
    Eikel D; Lampen A; Nau H
    Chem Res Toxicol; 2006 Feb; 19(2):272-8. PubMed ID: 16485903
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Docking and QSAR Studies of Aryl-valproic Acid Derivatives to Identify Antiproliferative Agents Targeting the HDAC8.
    Martínez-Pacheco H; Ramírez-Galicia G; Vergara-Arias M; Gertsch J; Fragoso-Vazquez JM; Mendez-Luna D; Abujamra AL; Cristina CL; Cecilia RM; Mendoza-Lujambio I; Correa-Basurto J
    Anticancer Agents Med Chem; 2017; 17(7):927-940. PubMed ID: 27774878
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Valproic acid, but not levetiracetam, selectively decreases HDAC7 and HDAC2 expression in human ovarian cancer cells.
    Kwiecińska P; Wróbel A; Taubøll E; Gregoraszczuk EŁ
    Toxicol Lett; 2014 Jan; 224(2):225-32. PubMed ID: 24200999
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anti-epileptic activity, toxicity and teratogenicity in CD1 mice of a novel valproic acid arylamide derivative, N-(2-hydroxyphenyl)-2-propylpentanamide.
    Cristóbal-Luna JM; Correa-Basurto J; Mendoza-Figueroa HL; Chamorro-Cevallos G
    Toxicol Appl Pharmacol; 2020 Jul; 399():115033. PubMed ID: 32387339
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Downregulation of TrkB Expression and Signaling by Valproic Acid and Other Histone Deacetylase Inhibitors.
    Dedoni S; Marras L; Olianas MC; Ingianni A; Onali P
    J Pharmacol Exp Ther; 2019 Sep; 370(3):490-503. PubMed ID: 31308194
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The histone deacetylase inhibitors suberoylanilide hydroxamic (Vorinostat) and valproic acid induce irreversible and MDR1-independent resistance in human colon cancer cells.
    Fedier A; Dedes KJ; Imesch P; Von Bueren AO; Fink D
    Int J Oncol; 2007 Sep; 31(3):633-41. PubMed ID: 17671692
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting AML1/ETO-histone deacetylase repressor complex: a novel mechanism for valproic acid-mediated gene expression and cellular differentiation in AML1/ETO-positive acute myeloid leukemia cells.
    Liu S; Klisovic RB; Vukosavljevic T; Yu J; Paschka P; Huynh L; Pang J; Neviani P; Liu Z; Blum W; Chan KK; Perrotti D; Marcucci G
    J Pharmacol Exp Ther; 2007 Jun; 321(3):953-60. PubMed ID: 17389244
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of Valproic Acid on the Class I Histone Deacetylase 1, 2 and 3, Tumor Suppressor Genes p21WAF1/CIP1 and p53, and Intrinsic Mitochondrial Apoptotic Pathway, Pro- (Bax, Bak, and Bim) and anti- (Bcl-2, Bcl-xL, and Mcl-1) Apoptotic Genes Expression, Cell Viability, and Apoptosis Induction in Hepatocellular Carcinoma HepG2 Cell Line.
    Sanaei M; Kavoosi F
    Asian Pac J Cancer Prev; 2021 Feb; 22(S1):89-95. PubMed ID: 33576217
    [TBL] [Abstract][Full Text] [Related]  

  • 15. HDAC inhibition delays cell cycle progression of human bladder cancer cells in vitro.
    Vallo S; Xi W; Hudak L; Juengel E; Tsaur I; Wiesner C; Haferkamp A; Blaheta RA
    Anticancer Drugs; 2011 Nov; 22(10):1002-9. PubMed ID: 21822119
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Three amino acid derivatives of valproic acid: design, synthesis, theoretical and experimental evaluation as anticancer agents.
    Luna-Palencia GR; Martinez-Ramos F; Vasquez-Moctezuma I; Fragoso-Vazquez MJ; Mendieta-Wejebe JE; Padilla-Martínez II; Sixto-Lopez Y; Mendez-Luna D; Trujillo-Ferrara J; Meraz-Rios MA; Fonseca-Sabater Y; Correa-Basurto J
    Anticancer Agents Med Chem; 2014; 14(7):984-93. PubMed ID: 24476311
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Multiple Molecular pathways explain the anti-proliferative effect of valproic acid on prostate cancer cells in vitro and in vivo.
    Shabbeer S; Kortenhorst MS; Kachhap S; Galloway N; Rodriguez R; Carducci MA
    Prostate; 2007 Jul; 67(10):1099-110. PubMed ID: 17477369
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The G1 phase arrest and apoptosis by intrinsic pathway induced by valproic acid inhibit proliferation of BGC-823 gastric carcinoma cells.
    Zhao X; Yang W; Shi C; Ma W; Liu J; Wang Y; Jiang G
    Tumour Biol; 2011 Apr; 32(2):335-46. PubMed ID: 21113745
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Exploring the biotransformation of N-(2-hydroxyphenyl)-2-propylpentanamide (an aryl valproic acid derivative) by CYP2C11, using in silico predictions and in vitro studies.
    Mendieta-Wejebe JE; Silva-Trujillo A; Bello M; Mendoza-Figueroa HL; Galindo-Alvarez NL; Albores A; Tamay-Cach F; Rosales-Hernández MC; Romero-Castro A; Correa-Basurto J
    J Pharm Pharmacol; 2020 Jul; 72(7):938-955. PubMed ID: 32307724
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cellular Effects of the Antiepileptic Drug Valproic Acid in Glioblastoma.
    Eckert M; Klumpp L; Huber SM
    Cell Physiol Biochem; 2017; 44(4):1591-1605. PubMed ID: 29212069
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.